Source: Hematology, Transfusion and Cell Therapy. Unidades: ICB, FCF
Assunto: LEUCEMIA
ABNT
GARNIQUE, Anali Del Milagro Bernabe et al. Hybrid histone deacetylase kinase inhibitor potentiates venetoclax induced cell death in chronic lymphocytic leukemia. Hematology, Transfusion and Cell Therapy, v. 47, n. 2, p. 1-5 art. 103757, 2025Tradução . . Disponível em: https://dx.doi.org/10.1016/j.htct.2025.103757. Acesso em: 30 abr. 2025.APA
Garnique, A. D. M. B., Carlos, J. A. E. G., Parducci, N. S., Tavares, M. T., Waitman, K. de B., Lima, K., et al. (2025). Hybrid histone deacetylase kinase inhibitor potentiates venetoclax induced cell death in chronic lymphocytic leukemia. Hematology, Transfusion and Cell Therapy, 47( 2), 1-5 art. 103757. doi:10.1016/j.htct.2025.103757NLM
Garnique ADMB, Carlos JAEG, Parducci NS, Tavares MT, Waitman K de B, Lima K, Lotufo LVC, Parise Filho R, Machado Neto JA. Hybrid histone deacetylase kinase inhibitor potentiates venetoclax induced cell death in chronic lymphocytic leukemia [Internet]. Hematology, Transfusion and Cell Therapy. 2025 ; 47( 2): 1-5 art. 103757.[citado 2025 abr. 30 ] Available from: https://dx.doi.org/10.1016/j.htct.2025.103757Vancouver
Garnique ADMB, Carlos JAEG, Parducci NS, Tavares MT, Waitman K de B, Lima K, Lotufo LVC, Parise Filho R, Machado Neto JA. Hybrid histone deacetylase kinase inhibitor potentiates venetoclax induced cell death in chronic lymphocytic leukemia [Internet]. Hematology, Transfusion and Cell Therapy. 2025 ; 47( 2): 1-5 art. 103757.[citado 2025 abr. 30 ] Available from: https://dx.doi.org/10.1016/j.htct.2025.103757